AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17121522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PGZ)
Number of subjects: 30
Study 17121522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 30
Study 12692844 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunostaining (using mouse monoclonal antibody pAb1801)
Number of subjects: 502
Study 12692844 — intervention group
Group type: EXPERIMENTAL
Intervention: pT1G3 disease
Number of subjects: 502
Study 12692844 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 staining
Number of subjects: 502
Study 10964288 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group treated for all positive antigens
Number of subjects: 18
Study 10964288 — intervention group
Group type: COMPARATOR
Intervention: Control group treated for all positive antigens, except study antigens
Number of subjects: 18
Study 10964288 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 18
Study 8858269 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat herb tea (Fagopyrum esculentum)
Number of subjects: 67
Study 8858269 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 67
Study 8858269 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat herb tea
Number of subjects: 67
Study 1516415 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg tablets, three times daily for 48 hours prior to testing)
Number of subjects: 10
Study 1516415 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 10
Study 1516415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Indomethacin and Placebo (during repeated methacholine challenges)
Number of subjects: 10
Study 6332780 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperatively administered plasma proteins
Number of subjects: 94
Study 6332780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasma proteins)
Number of subjects: 94
Study 31466479 — intervention group
Group type: EXPERIMENTAL
Intervention: External cardioversion
Number of subjects: 230
Study 31466479 — intervention group
Group type: COMPARATOR
Intervention: Internal cardioversion
Number of subjects: 230
Study 30129327 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical approaches (lymphatic‐venous anastomosis (LVA), vascularized lymph node transfer (VLNT))
Number of subjects: 0
Study 30129327 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 27389678 — intervention group
Group type: EXPERIMENTAL
Intervention: SILC using a novel instrument (Group A)
Number of subjects: 150
Study 27389678 — intervention group
Group type: EXPERIMENTAL
Intervention: SILC using a conventional instrument (Group B)
Number of subjects: 150
Study 27389678 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (Group C)
Number of subjects: 150
Study 24901076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity eccentric contractions with blood flow restriction (BFR)
Number of subjects: 9
Study 24901076 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity eccentric contractions without blood flow restriction (BFR)
Number of subjects: 9
Study 22237175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus therapeutic DNA vaccine (TransVax) administered before conditioning and at 1, 3, and 6 months after transplantation.
Number of subjects: 108
Study 22237175 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered before conditioning and at 1, 3, and 6 months after transplantation.
Number of subjects: 108
Study 22237175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus therapeutic DNA vaccine (TransVax)
Number of subjects: 108
Study 22237175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20609187 — intervention group
Group type: EXPERIMENTAL
Intervention: Step sodium profile
Number of subjects: 22
Study 20609187 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear sodium profile
Number of subjects: 22
Study 20609187 — intervention group
Group type: COMPARATOR
Intervention: Control (steady sodium)
Number of subjects: 22
Study 18343802 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 21
Study 15970919 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery technique over a consecutive 4‐day period
Number of subjects: 210
Study 15970919 — intervention group
Group type: COMPARATOR
Intervention: Control group (monitored without intervention)
Number of subjects: 210
Study 12567364 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with supplementary foot block (0.5% bupivicaine)
Number of subjects: 42
Study 12567364 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 42
Study 10616845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 microg/kg per min)
Number of subjects: 126
Study 10616845 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (0.5 microg/kg per min)
Number of subjects: 126
Study 10616845 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo)
Number of subjects: 126
Study 8830827 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL‐1R therapy
Number of subjects: 14
Study 1330678 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nedocromil sodium, 4 mg q.i.d.
Number of subjects: 23
Study 1330678 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate, 200 micrograms q.i.d.
Number of subjects: 23
Study 1330678 — intervention group
Group type: COMPARATOR
Intervention: Comparison of beclomethasone to nedocromil sodium
Number of subjects: 23
Study 3910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 40 mg/d
Number of subjects: 8
Study 3910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 80 mg/d
Number of subjects: 8
Study 3910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 120 mg/d
Number of subjects: 8
Study 3910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 160 mg/d
Number of subjects: 8
Study 3910302 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen treatment (after 5 months)
Number of subjects: 8
Study 30316147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 107
Study 30316147 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 107
Study 30316147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 107
Study 30316147 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 107
Study 27229908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 60
Study 27229908 — intervention group
Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 60
Study 23812579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapse surgery with concurrent tension-free vaginal tape (TVT)
Number of subjects: 80
Study 23812579 — intervention group
Group type: COMPARATOR
Intervention: Prolapse surgery alone (no TVT)
Number of subjects: 80
Study 22549748 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 81
Study 22549748 — intervention group
Group type: COMPARATOR
Intervention: Standard dry dressing
Number of subjects: 81
Study 22549748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NPWT and dry dressing)
Number of subjects: 81
Study 22549748 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT
Number of subjects: 81
Study 22549748 — intervention group
Group type: COMPARATOR
Intervention: Dry dressing
Number of subjects: 81
Study 20138267 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of AMH measured on cycle day 3
Number of subjects: 60
Study 20138267 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH level ≥3.01 ng/mL
Number of subjects: 60
Study 20138267 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH level ≥3.2 ng/mL
Number of subjects: 60
Study 19192863 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement group ($30.00 for each consecutive opioid-free urine sample)
Number of subjects: 22
Study 19192863 — intervention group
Group type: COMPARATOR
Intervention: Control group ($4.00 for completing assessments)
Number of subjects: 22
Study 15794398 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized eligibility assessment for MS diagnosis
Number of subjects: 0
Study 12023995 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (prophylactic inhalation)
Number of subjects: 37
Study 12023995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11888456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation (tidal volume 4 mL/kg, respiratory rate 15/min)
Number of subjects: 80
Study 11888456 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation (tidal volume 10 mL/kg, respiratory rate 10/min)
Number of subjects: 80
Study 11888456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation
Number of subjects: 80
Study 11888456 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation
Number of subjects: 80
Study 9861280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 3 months
Number of subjects: 1530
Study 9861280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 6 months
Number of subjects: 1530
Study 9861280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 12 months
Number of subjects: 1530
Study 9861280 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment every 3 months
Number of subjects: 1530
Study 7622647 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% quaternium‐18 bentonite lotion
Number of subjects: 211
Study 7622647 — intervention group
Group type: COMPARATOR
Intervention: Untreated control sites
Number of subjects: 211
Study 2222900 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN alpha (1,200 IU/day)
Number of subjects: 19
Study 2222900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 342174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fenoterol (5.6 microgram)
Number of subjects: 12
Study 342174 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose fenoterol (32.7 microgram)
Number of subjects: 12
Study 342174 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fenoterol (127.5 microgram)
Number of subjects: 12
Study 342174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 microgram)
Number of subjects: 12
Study 6356793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (150 mg daily)
Number of subjects: 29
Study 6356793 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 29
Study 29226570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based therapy
Number of subjects: 394
Study 29226570 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus-based therapy
Number of subjects: 394
Study 26546987 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PWT)
Number of subjects: 41
Study 26546987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Speed Yoga
Number of subjects: 41
Study 26546987 — intervention group
Group type: COMPARATOR
Intervention: Control (nonexercise group)
Number of subjects: 41
Study 23682170 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training including balance exercises and lower limb strength activities twice a week for 4 months
Number of subjects: 126
Study 23682170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 23153666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular fixation (case group)
Number of subjects: 53
Study 23153666 — intervention group
Group type: COMPARATOR
Intervention: No fibular fixation (control group)
Number of subjects: 53
Study 20704266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bead formulation with faster dissolution rate (80% dissolved in 41 min)
Number of subjects: 0
Study 20704266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bead formulation with slower dissolution rate (80% dissolved in 114 min)
Number of subjects: 0
Study 20704266 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo bioequivalence study
Number of subjects: 0
Study 18767577 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus psychotherapy
Number of subjects: 47
Study 18767577 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 47
Study 16261102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: Galvanic current
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: PEMF
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: Diadynamic current
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: Permanent magnets
Number of subjects: 14
Study 16261102 — intervention group
Group type: COMPARATOR
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 14
Study 14644633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,16-androstadien-3-one (androstadienone) exposure (250 microM)
Number of subjects: 0
Study 14644633 — intervention group
Group type: COMPARATOR
Intervention: Control for sensory detection of the steroid
Number of subjects: 0
Study 10665727 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeman‐Samuelson hydroxyapatite‐coated (FS HA)
Number of subjects: 38
Study 10665727 — intervention group
Group type: COMPARATOR
Intervention: Miller‐Galante II (MG II)
Number of subjects: 38
Study 9031103 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy
Number of subjects: 41
Study 1341376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation of blood
Number of subjects: 1527
Study 6375603 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal anastomoses first
Number of subjects: 30
Study 6375603 — intervention group
Group type: COMPARATOR
Intervention: Distal anastomoses first
Number of subjects: 30
Study 31310354 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe AAC (AAC24 score >1)
Number of subjects: 1024
Study 31310354 — intervention group
Group type: COMPARATOR
Intervention: Low AAC (score 0 and 1)
Number of subjects: 1024
Study 30028023 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56+ T-ALL
Number of subjects: 493
Study 30028023 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56 expression combined with MRD-based high risk assignment
Number of subjects: 493
Study 27144930 — intervention group
Group type: EXPERIMENTAL
Intervention: Kombiglyze XR (saxagliptin 5 mg/metformin 2000 mg) daily
Number of subjects: 100
Study 24732081 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 48
Study 24732081 — intervention group
Group type: COMPARATOR
Intervention: Total caries removal (TCR)
Number of subjects: 48
Study 22984089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted games (AG)
Number of subjects: 20
Study 22984089 — intervention group
Group type: COMPARATOR
Intervention: Placebo activities (PL)
Number of subjects: 20
Study 20499150 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive women
Number of subjects: 535
Study 20499150 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive men
Number of subjects: 535
Study 20499150 — intervention group
Group type: COMPARATOR
Intervention: HIV negative men
Number of subjects: 535
Study 20499150 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples overall
Number of subjects: 535
Study 18620577 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+AQ
Number of subjects: 227
Study 18620577 — intervention group
Group type: COMPARATOR
Intervention: AM-L
Number of subjects: 227
Study 15951679 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed questionnaire
Number of subjects: 875
Study 15951679 — intervention group
Group type: COMPARATOR
Intervention: Web questionnaire with personalized feedback
Number of subjects: 875
Study 15951679 — intervention group
Group type: COMPARATOR
Intervention: Plain Web questionnaire
Number of subjects: 875
Study 12532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy initiated early after acute coronary syndrome
Number of subjects: 0
Study 12532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 12532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy prescribed during initial hospitalization for ACS
Number of subjects: 0
Study 10583717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 15 cmH2O
Number of subjects: 24
Study 10583717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 30 cmH2O
Number of subjects: 24
Study 10583717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 60 cmH2O
Number of subjects: 24
Study 9062806 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow Rate (PEFR) measurement
Number of subjects: 1315
Study 1874765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated throughout the procedure, released postoperatively after compressive dressing; splint used for three days (Group I)
Number of subjects: 121
Study 1874765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated throughout the procedure, no splint, continuous passive motion started immediately (Group II)
Number of subjects: 121
Study 1874765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively, hemostasis by cauterization, compressive dressing applied, splint used for three days (Group III)
Number of subjects: 121
Study 1874765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively, reinflated after hemostasis, compressive dressing applied, continuous passive motion started immediately (Group IV)
Number of subjects: 121
Study 7103152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized nasal dexamethasone phosphate
Number of subjects: 45
Study 7103152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29665620 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory nutrition supplement (AINS) consisting of long chain n-3 PUFA, vitamin C, α-tocopherol, green tea extract, and lycopene for 8 weeks
Number of subjects: 70
Study 29665620 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 70
Study 26944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1mg per dose, up to 40 times per day)
Number of subjects: 0
Study 26944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2mg/day)
Number of subjects: 0
Study 26944021 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray
Number of subjects: 0
Study 26944021 — intervention group
Group type: COMPARATOR
Intervention: Varenicline placebo
Number of subjects: 0
Study 24744188 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-m biliopancreatic (BP)-limb and a 60-cm alimentary (A)-limb (n=93)
Number of subjects: 187
Study 24744188 — intervention group
Group type: COMPARATOR
Intervention: 150-cm A-limb and a 60-cm BP-limb (n=94)
Number of subjects: 187
Study 24744188 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-m BP-limb group
Number of subjects: 187
Study 24744188 — intervention group
Group type: COMPARATOR
Intervention: 150-cm A-limb group
Number of subjects: 187
Study 24744188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 187
Study 23114512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema
Number of subjects: 117
Study 23114512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant-filled applicator
Number of subjects: 117
Study 23114512 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository
Number of subjects: 117
Study 20739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO₃) 0.3 g/kg body weight
Number of subjects: 25
Study 20739719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19052191 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered electronic media intervention; 20-week duration; included setting electronic media use goals, using TV Allowance device and ENUFF software.
Number of subjects: 21
Study 19052191 — intervention group
Group type: COMPARATOR
Intervention: Control group; no specific intervention mentioned.
Number of subjects: 21
Study 19052191 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered electronic media intervention; 20-week duration.
Number of subjects: 21
Study 15836964 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 21
Study 15836964 — intervention group
Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 21
Study 12580842 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BMI > 25 and polycystic ovaries
Number of subjects: 68
Study 12580842 — intervention group
Group type: COMPARATOR
Intervention: Women with BMI ≤ 25 and normal ovaries
Number of subjects: 68
Study 12580842 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BMI ≤ 25 and polycystic ovaries
Number of subjects: 68
Study 12580842 — intervention group
Group type: COMPARATOR
Intervention: Women with BMI > 25 and normal ovaries
Number of subjects: 68
Study 10506264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (12 mg/kg)
Number of subjects: 27065
Study 10506264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (5 mg/kg)
Number of subjects: 27065
Study 10506264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 27065
Study 10506264 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27065
Study 8699065 — intervention group
Group type: EXPERIMENTAL
Intervention: FLA‐ELISA followed by immunoblotting
Number of subjects: 0
Study 1911501 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg MS bolus and subsequent saline infusion (n = 13)
Number of subjects: 31